Day One Biopharma Expands to ADCs with $55M Drug Acquisition
"Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
- Latest
- Trending
"Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
Ventyx Biosciences, Inc. (VTYX) is a high-risk investment with negative net income and high debt ratio, but analysts recommend buying ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.